Pharmafile Logo
Pharmafocus logo
Advanced Search

migraine

Showing 15 posts of 42 posts found.

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025
Research and Development Neurology, Teva, migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …

News

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025
Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …

News

NICE recommends migraine treatment for NHS use

April 11, 2024
Medical Communications NHS, NICE, Neurology, migraine

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …

News

American Heart Association awards $2.1m to research link between migraine, strokes and CVD

July 27, 2023
Research and Development American Heart Association, Cardiology, cvd, migraine, stroke

The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …

News

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

June 2, 2023
Medical Communications NHS, NICE, Neurology, Pfizer, migraine

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …

News
brain-1845962_960_720

New study challenges link between stress and migraines

January 25, 2021
Sales and Marketing Curelator, migraine

Digital health platform Curelator has announced new data that shows a lack of association between increased stress and migraine attacks. …

News

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …

News

Axsome’s late-stage study of experimental depression drug misses main trial goal

March 31, 2020
Manufacturing and Production Depressive Disorder, MDD, depression, migraine

Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …

News
teva_copy

Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine

March 12, 2020
Sales and Marketing NICE, Teva, ajovy, migraine, pharma

NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …

News

Lundbeck’s Vyepti secures US approval for migraine prevention

February 24, 2020
Sales and Marketing FDA, Lundbeck, Vyepti, migraine, pharma

Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention of migraine in adult patients. …

News
teva_copy

FDA approves Teva’s Ajovy autoinjector for treatment of migraine

January 29, 2020
Research and Development, Sales and Marketing FDA, Teva, ajovy, migraine, pharma

Israeli pharma firm Teva has revealed that the FDA has chosen to award approval to its autoinjector device for the …

News

Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine

October 15, 2019
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma

Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …

News

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

September 26, 2019
Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …

News

Lundbeck acquires Alder in $2bn migraine treatment move

September 16, 2019
Sales and Marketing Alder, Lundbeck, eptinezumab, migraine

Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition …

News
novartis_side_building

4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019
Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026